Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
91results about "Relaxins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
ActiveUS20050256028A1Effective treatmentAntibacterial agentsBiocideMenstrual cycle phaseNervous system
Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity / sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and / or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.
Owner:PALO ALTO INVESTORS
Non-aqueous single phase vehicles and formulations utilizing such vehicles
InactiveUS20050008661A1Increase stickinessReduce occlusionPowder deliveryPeptide/protein ingredientsEngineeringSolvent
The present invention includes materials and methods for providing vehicles useful for providing drug formulations that address the potential drawbacks of known nonaqueous formulations. In particular, the present invention includes nonaqueous vehicles that are formed using a combination of polymer and solvent that results in a vehicle that is miscible in water. The nonaqueous vehicles facilitate the formulation of drug formulations that are stable over time, even when stored at, or exposed to, elevated temperatures. Moreover, the miscible vehicles of the present invention allow the preparation of drug formulations that work to reduce the occurrence of partial or complete occlusions of the delivery conduits included in delivery devices used to administer the drug formulations.
Owner:DURECT CORP
Fc Variants Having Decreased Affinity for FcyRIIc
Owner:XENCOR INC
Non-aqueous single phase vehicles and formulations utilizing such vehicles
InactiveUS20050276856A1Decrease in levelLower Level RequirementsPowder deliveryPeptide/protein ingredientsMedicineDelivery vehicle
Owner:DURECT CORP
Method of promoting angiogenesis using relaxin
InactiveUS6211147B1Organic active ingredientsPeptide/protein ingredientsRelaxinAngiogenesis growth factor
Relaxin is useful for promoting angiogenesis and the treatment of infections or ischemic wounds where the injury results from lack of oxygen due to poor circulation.
Owner:CORTHERA INC
Use of relaxin to restore maternal physiology in pregnancies conveived by assisted reproductive technologies
ActiveUS20140100159A1Reduce riskImproving embryo developmentPeptide/protein ingredientsRelaxinsRelaxin-3Obstetrics
The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Use of relaxin treat diseases related to vasoconstriction
InactiveUS6723702B2Safety profileImprove securityElectrotherapyPeptide/protein ingredientsArteriolar VasoconstrictionVascular disease
The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.
Owner:RUTGERS THE STATE UNIV +2
Use of relaxin to treat diseases related to vasoconstriction
InactiveUS20040266685A1Safety profileImprove securityPeptide/protein ingredientsRelaxinsArteriolar VasoconstrictionDisease
The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.
Owner:THE UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY ROBERT WOOD JOHNSON MEDICAL SCHOOL +2
Synthetic linear apelin mimetics for the treatment of heart failure
InactiveUS20140155315A1Extended half-lifeIncrease constraintsNervous disorderPeptide/protein ingredientsCardiac fibrosisVentricular tachycardia
The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13 Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG
Methods and compositions for control of fetal growth via modulation of relaxin
InactiveUS20060247172A1Increase probabilitySufficient amountPeptide/protein ingredientsMetabolism disorderDiseaseRelaxin-3
The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to identify compounds that modulate relaxin and / or relaxin receptor activity. The invention further relates to gene therapy methods utilizing relaxin and relaxin-related sequences for the treatment and prevention of diseases related to fetal growth and placental insufficiency.
Owner:CORTHERA INC
Methods and compositions for control of fetal growth via modulation of relaxin
InactiveUS20080108572A1Increase probabilitySufficient amountPeptide/protein ingredientsMetabolism disorderDiseaseRelaxin-3
The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to identify compounds that modulate relaxin and / or relaxin receptor activity. The invention further relates to gene therapy methods utilizing relaxin and relaxin-related sequences for the treatment and prevention of diseases related to fetal growth and placental insufficiency.
Owner:CORTHERA INC
Methods and compositions for treating plasticity in a subject
InactiveUS20060069012A1Stay plasticLowering long-term potentiationOrganic active ingredientsNervous disorderPhysiologySubject matter
Methods and compositions for at least maintaining plasticity in a system of a subject are provided. Embodiments of the subject methods include lowering long term potentiation in said subject in a manner effective to at least maintain plasticity of a system in said subject.
Owner:PALO ALTO INVESTORS
Boc and Fmoc solid phase peptide synthesis
A solid phase method for synthesizing a peptide containing three or more amino acid residues utilizing both Boc and Fmoc protected amino acids and a chloromethylated polystyrene resin.
Owner:IPSEN MFG IRELAND
Method for producing a device applicable to biological tissues, particularly a patch for treating damaged tissues, and a device obtained by said method
ActiveUS8628787B2Slow kineticsEasy to controlBiocidePeptide/protein ingredientsHaemostatic functionCross-link
The present invention relates to a device consisting of cross-linked nanofibrillary fibrin supported on and rooted to a microporous nonwoven fabric consisting of a biocompatible synthetic polymer material. An active ingredient is advantageously dispersed in the fibrin layer. The fibrin layer does not have a haemostatic function, but is suitable for retaining the active ingredient and releasing it with controlled kinetics. The device forming the object of the invention, preferably in the form of patches, is useful for in vitro cell cultures or for treating tissues damaged by wounds or necrosis, such as cardiac walls bearing the sequelae of infarction, or a tissue damaged by a diabetic ulcer. The patch according to the invention can be manufactured by inducing the polymerisation of the fibrin, under suitable conditions, directly on the support layer, which is suitably impregnated with thrombin (at least in a superficial portion of its thickness), and which has been conveniently prepared by means of a spray phase-inversion technique.
Owner:CONSIGLIO NAT DELLE RICERCHE +1
Method for remodeling bone and related sutures
InactiveUS20060052304A1Inhibits receptor activityIncrease heightPeptide/protein ingredientsAntipyreticRelaxin receptorBiomedical engineering
The invention relates to the discovery that relaxin receptors exist in bone and related sutures. As such, bone can be remodeled, repaired, removed or grown. Particularly, the invention pertains to a method for modifying a target bone by administering a relaxin compound which binds to relaxin receptors and by monitoring a change in the target bone. The invention further encompasses methods of modifying the height of a human subject.
Owner:CORTHERA INC
Solid-phase synthesis method of human relaxin-2
InactiveCN102180964AHigh yieldSimple production processRelaxinsPeptide preparation methodsChemical synthesisCombinatorial chemistry
The invention discloses a solid-phase synthesis method of human relaxin-2, which comprises the following steps of: 1) solid-phase synthesis of a single-ring chain A; 2) solid-phase synthesis of a chain B; and 3) chemical synthesis of the human relaxin-2. By using the method to produce the human relaxin-2, the yield is high and can be up to 74-82%. The method disclosed by the invention has the advantages of convenient production steps and no impurity production in the production process, and effectively solves the problems that the solid-phase synthesis of the chain B of the human relaxin-2 isdifficult to complete by the Fmoc strategy and the synthesis process is too complicated.
Owner:山东长肽医药科技有限公司
Methods and compositions for control of fetal growth via modulation of relaxin
InactiveUS20060247163A1Increase probabilitySufficient amountBiocidePeptide/protein ingredientsDiseaseRelaxin-3
The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to identify compounds that modulate relaxin and / or relaxin receptor activity. The invention further relates to gene therapy methods utilizing relaxin and relaxin-related sequences for the treatment and prevention of diseases related to fetal growth and placental insufficiency.
Owner:CORTHERA INC
Relaxin fusion polypeptides and uses thereof
The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Relaxin fusion polypeptides and uses thereof
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Method and compositions for the treatment of diabetes and related complications
InactiveUS20060281669A1Improve the situationNervous disorderPeptide/protein ingredientsDiabetes mellitusDisease
Owner:SKY BIOHEALTH SOLUTIONS
Relaxin Analogs
InactiveUS20110130332A1Improve effectivenessResponse can be unwantedPeptide/protein ingredientsRelaxinsNucleotide compositionPolypeptide composition
Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Peptide Synthesis
ActiveUS20110039778A1Improve solubilityGood flexibilityPeptide/protein ingredientsMuscular disorderSolubilityRelaxin
A process for producing an insulin type peptide, for example a relaxin, involving oxidizing a methionine residue on a B-chain having cysteine residues and combining the B chain with an A chain having cysteine residues to form a peptide having intermolecular disulphide links and biological activity. Novel synthetic relaxin 1 and methionine oxidized relaxins and Met(O) B-chains having enhanced solubility are disclosed.
Owner:CHEM & BIOPHARML LAB OF PATRAS
Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues
InactiveUS20050143299A1Promote rapid maturationRapidly organizationBiocideNervous disorderAdjuvantSmell loss
On the basis of the experimental results it has emerged that relaxin has a pro-differentiating effect on stem cells. It is therefore suggested the use of this hormone as principal component of a drug for the treatment of all those situations that find or will find benefit from the use of stem cells for the reconstruction of tissues damaged by traumatic events or by ischemic-inflammatory-degenerative diseases. It is also suggested the use of relaxin for the treatment of syndromes deriving from the missing activation of stem cells during fetal development (at subsequent somatic-functional maturation), such as for example hypogonotropic hypogonadism with anosmia (Kallman's syndrome).
Owner:BIGAZZI MARIO
Methods of modulating apoptosis by administration of relaxin agonists or antagonists
InactiveUS20050032683A1Increase and decreases functional activity of moleculeNervous disorderPeptide/protein ingredientsRelaxinApoptosis
The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
Owner:MOLECULAR MEDICINE RES INST
Human relaxin 2 precursor and preparation method thereof
InactiveCN102603888AIncrease secreted expressionReduced Excision CostsFungiRelaxinsSecretion expressionC-peptide
The invention relates to a human relaxin 2 precursor and a preparation method thereof. According to the human relaxin 2 precursor, a B chain and an A chain of a natural human relaxin 2 are connected through an AsnGlyPheAsnGly artificial C peptide in a B-C-A order, so as to form a structure of a non-natural human relaxin 2 precursor. An amino acid sequence of the human relaxin 2 precursor is shown by a sequence 1 in a sequence list and is named as rhR2. According to the human relaxin 2 precursor and an optimized gene thereof, provided by the invention, a secreted expression amount of the human relaxin 2 precursor in pichia pastoris is greatly improved. The C peptide of the human relaxin 2 precursor is removed by using cheap hydroxyl amine rather than expensive TPCK (Tosyl-Phenylalanine Chloromethyl-Ketone)-trypsinase, so that the cost of removing the C peptide is reduced.
Owner:HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and / or conditions relating to fibrosis.
Owner:BRISTOL MYERS SQUIBB CO
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
Owner:BRISTOL MYERS SQUIBB CO
Relaxin peptide synthesis
Owner:PATRAS CHEM & BIOPHARMACEUTICAL LAB
Polynucleotides encoding relaxin
The invention relates to mRNA therapy for the treatment of fibrosis and / or cardiovascular disease, mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin, mRNAs of the invention are preferably encapsulated in lipid nano particles (LNPs) to effect efficient delivery to cells and / or tissues in subjects, when administered thereto, mRNA therapies of the invention increase and / or restore deficient levels of relaxin expression and / or activity in subjects, mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
Owner:MODERNATX INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com